The National Cancer Institute has made a new five-year grant totaling 3519965 to the laboratory of Edison Liu M.D. president and CEO of The Jackson Laboratory JAX to fund a multi-pronged investigation of a genomic fingerprint found in some triple-negative breast cancers TNBC with the goal of finding new therapeutic approaches for these most difficult-to-treat cancers.Breast cancer is the most prevalent cancer in the U.S. population and is second only to lung cancer as the most deadly. But the term breast cancer is also a generalization There are several kinds of breast cancer each driven by different genetic factors. A womans cancer may test positive for a protein called HER2 human epidermal growth factor or for receptors that enable the cancer to use the female hormones estrogen or progesterone as fuel to grow.Specific therapies are now available to target these HER2- estrogen- or progesterone-positive cancers. But not so for the breast cancers known as triple-negative because they dont fall into any of these three categories. Accounting for about 10 to 15 percent of all breast cancers triple-negative breast cancer TNBC also tends to grow and spread faster and is more common among women who are under age 40 who are African-American or who carry a BRCA1 mutation.In 2016 the Liu lab published their discovery of a distinct genomic configuration found in about half of all triple-negative breast ovarian and endometrial cancers which they dubbed the tandem duplicator phenotype TDP. Since then the lab has published many additional findings on how mutations in TP53 and BRCA1 genes give rise to the TDP.Liu says the researchers will use the new grant 703993 for the first of five years to deploy a combination of computational analyses studies in new mouse models of breast cancer and experiments using human cancer cell lines that are either proficient or deficient for BRCA1 activity.If successful Liu says the funded research will uncover the root causes of a significant form of genomic instability in human cancer the TDP define the mutational dynamics leading to cancer formation in this condition and generate model systems that can lead to the development of new and directed therapeutics against cancer growth.
🔍 Key Information
📄
Tender Reference No.
458582379
📅
Publication Date
08 Dec 2020
🌐
Sector
Banking, Finance, Insurance and Securities (BFIS)
📝
Notice Type
News
📍
Location
United states
📁
Documents & Downloads
No documents found
🏷️ CPV
No CPV found
Need help with this bid?
Our bid experts can help you find, evaluate & win more tenders.